Multivalent Clostridial Toxin Targeting Specific Cell Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Clostridial toxin therapies face challenges such as undesirable side effects due to toxin dispersal beyond targeted areas and eliciting an immune response, requiring higher doses and frequent treatments, which limits their effectiveness and expands their use beyond myo-relaxant applications.
Innovation Solution
Development of multivalent Clostridial toxins with multiple binding domains that can specifically target various cell types, reducing dispersal and immunogenicity, and expanding therapeutic applications to include sensory and non-neuronal disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If larger doses of Clostridial toxin are administered to achieve beneficial effects, then therapeutic efficacy is improved, but toxin dispersal to non-targeted areas increases causing undesirable side effects
Solution Approach 1:
The toxin molecule is segmented into distinct functional domains: a binding domain for targeted cell recognition, a translocation domain for cellular entry, and an enzymatic domain for neurotransmitter release inhibition. This segmentation allows the binding domain to guide the toxin specifically to target cells while the enzymatic domain remains confined to intracellular action, preventing extracellular dispersal effects.
Solution Approach 2:
The binding domain acts as an intermediary that mediates between the toxin and target cell receptors. It provides specificity by recognizing and binding to particular cell surface markers, ensuring the toxin is delivered only to intended targets and not dispersed to non-targeted areas.
2Reliability
If larger doses of Clostridial toxin are administered, then therapeutic benefit is enhanced, but immune response against the toxin increases reducing treatment responsiveness
Solution Approach 1:
The toxin is divided into domains with the binding domain serving as a separate functional unit. This segmentation allows modification of the binding domain to reduce immunogenicity while preserving the enzymatic domain's therapeutic function, enabling repeated treatments without significant immune response.
Solution Approach 2:
The amino acid sequence of the binding domain is modified through mutagenesis to alter its immunogenic properties. These parameter changes in the protein structure reduce antibody recognition and immune response while maintaining the domain's ability to bind target cells and deliver the therapeutic effect.
3Adaptability or versatility
If Clostridial toxin is used for applications beyond myo-relaxant uses, then therapeutic versatility is expanded, but specificity to target cell types decreases leading to off-target effects
Solution Approach 1:
The toxin platform is designed with universal functional domains that can be combined with different binding domain variants. The conserved translocation and enzymatic domains provide core therapeutic function, while interchangeable binding domains enable targeting of different cell types, achieving multi-functionality across neurological, sensory, and non-neuronal applications.
Solution Approach 2:
Different binding domains with specific local properties are assigned to target different cell types. Each binding domain is optimized for its specific target's surface markers, ensuring high specificity at the local interaction level while the overall toxin structure remains consistent for efficient translocation and enzymatic action.
Data Source
AI summary
The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.